Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus
نویسندگان
چکیده
منابع مشابه
The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
BACKGROUND Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of pharmacologic agents developed for the treatment of type 2 diabetes mellitus (T2DM). Their unique mechanism of action is independent of pancreatic beta-cell function or the degree of insulin resistance, giving these agents the potential for use in combination with any of the existing classes of glucose-lowering age...
متن کاملRenal Sodium - Glucose Cotransporter Inhibition in the Management of Type 2 Diabetes 2 Mellitus 3
Revised 8-19-2015 (LOA) 1 Renal Sodium-Glucose Cotransporter Inhibition in the Management of Type 2 Diabetes 2 Mellitus 3 Muhammad A Abdul-Ghani, MD, PhD, Luke Norton, Ph.D., and Ralph A DeFronzo, MD 4 Division of Diabetes, University of Texas Health Science Center at San Antonio, Texas, USA 5 6
متن کاملSodium Glucose Co transporter 2 (SGLT2) Inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus
The low affinity sodium glucose cotransporter (SGLT2) plays a major role in physiology of glucose reabsorption from proximal part of kidney. Almost all glucose excreted through glomerular filtration, is reabsorbed via SGLT2 until blood glucose level reaches to its threshold value for glucose excretion i.e. ~180mg/dl. Increasing the glucose excretion by inhibiting the SGLT2 is the novel approach...
متن کاملRenal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
The incidence of renal-related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active- and placebo-controlled trials (N = 5598) and in a 104-week study vs glimepiride (N = 1450) was low and similar in canagliflozin and non-canagliflozin groups. In the study vs glimepiride, canagliflozin was associated with an initial ac...
متن کاملRenal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
BACKGROUND The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect of 8 weeks' sodium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in subjects with type 1 diabetes mellitus (T1D). METHODS AND RESULTS Inulin (glomerular filtration rate; GFR) and paraaminohippurate (effective renal plasma flow) cleara...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hormone and Metabolic Research
سال: 2018
ISSN: 0018-5043,1439-4286
DOI: 10.1055/a-0794-7026